Evidence map›Paper›PMID 37195162›Full record

ArticleRhode Island medical journal (2013)2023

Effectiveness of Monoclonal Antibody Therapy for Preventing COVID-19 Hospitalization and Mortality in a Statewide Population.

Laura C Chambers, Huong T Chu, Nickolas Lewis, Gauri Kamat, Taylor Fortnam, Philip A Chan, Leanne Lasher, Joseph W Hogan

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Rhode Island medical journal (2013), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Laura C Chamberswas Lead of the COVID-19 Data and Analytics Program at the Rhode Island Department of Health in Providence, RI, when this work was completed. Dr. Chambers is now a Lead Research Scientist and Assistant Professor of the Practice of Epidemiology in the Department of Epidemiology at Brown University in Providence, RI.
Huong T Chuwas the Analytics Team Lead in the COVID-19 Data and Analytics Program at the Rhode Island Department of Health in Providence, RI, when this work was completed. Dr. Chu is now a doctoral student in the Department of Health Metrics Sciences at the University of Washington in Seattle, WA.
Nickolas Lewisdoctoral student in the Department of Biostatistics at Brown University in Providence, RI.
Gauri Kamatdoctoral student in the Department of Biostatistics at Brown University in Providence, RI.
Taylor Fortnamoctoral student in the Department of Biostatistics at Brown University in Providence, RI.
Philip A ChanConsultant Medical Director at the Rhode Island Department of Health and an Associate Professor in the Department of Medicine at Brown University in Providence, RI.
Leanne LasherChief COVID-19 Data and Analytics Officer at the Rhode Island Department of Health in Providence, RI, when this work was completed. She is now the Senior Director of Public Health Research and Business Intelligence at the Association of State and Territorial Health Officers in Arlington, VA.
Joseph W HoganProfessor and Chair of the Department of Biostatistics at Brown University in Providence, RI.
Brown University · USRhode Island Department of Health · USInstitute for Health Metrics and Evaluation · US

Funding

HIV and Other Infectious Consequences of Substance UseT32DA013911 · NIDA · MIRIAM HOSPITAL · PI TRACI C GREEN, JOSIAH D RICH · 2001 to 2026
$9.6M
The Brown Initiative in HIV and AIDS Clinical Research for Minority CommunitiesR25MH083620 · NIMH · MIRIAM HOSPITAL · PI NUNN, AMY STEWART · 2008 to 2025
$3.7M
NIDA NIH HHS T32 DA013911NIMH NIH HHS R25 MH083620
6 · The paper itself

Abstract

backgroundMonoclonal antibody (MAB) treatments for COVID-19 received Emergency Use Authorization in the United States.

methodsWe used surveillance data from Rhode Island to conduct a retrospective, statewide cohort study to estimate the effectiveness of MABs for preventing hospitalization and death during periods when Alpha and Delta variants were predominant.

resultsFrom 1/17/2021-10/26/2021, 285 long-term congregate care (LTCC) residents and 3,113 non-congregate patients met our eligibility criteria and received MAB; they were matched to 285 and 6,226 controls, respectively. Among LTCC residents, 8.8% (25/285) of patients who received MAB were hospitalized or died compared to 25.3% (72/285) of those who did not receive MAB (adjusted difference=16.7%, 95% confidence interval CI=11.0-22.3%). Among non-congregate patients, 4.5% (140/3,113) of patients who received MAB were hospitalized or died compared to 11.8% (737/6,226) of those who did not receive MAB (adjusted difference=7.2%, 95% CI=6.0-8.4%).

conclusionsAdministration of MABs led to an absolute reduction in hospitalization or death during periods when Alpha and Delta variants were predominant.

Indexed as

COVID-19Antibodies, MonoclonalCohort StudiesHospitalizationHumansRetrospective StudiesSARS-CoV-2Antibodies, MonoclonalCOVID-19monoclonal antibody therapySARS-CoV-2treatment effectiveness

Identifiers

PMID37195162
PMCPMC11457867
OpenAlexW4376872332

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.